Exelixis Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Exelixis (EXEL) PT Raised to $33 at Needham & Company
February 13, 2019 10:52 AM ESTNeedham & Company analyst Chad Messer raised the price target on Exelixis (NASDAQ: EXEL) to $33.00 (from $30.00) while maintaining a Buy rating.
Messer commented, "Exelixis reported $176M in Cabo sales in 4Q:18, an 8% increase q/q. FY18 Cabo sales were $619M, a 44% increase... More
Exelixis (EXEL) PT Raised to $33 at Guggenheim Following 4Q
February 13, 2019 10:01 AM ESTGuggenheim analyst Michael Schmidt raised the price target on Exelixis (NASDAQ: EXEL) to $33.00 (from $31.00) while maintaining a Buy rating following the company's 4Q earnings report. EXEL reported 4Q18 revenue of $229M, 22% above Street consensus of $188M. Non-GAAP diluted EPS was 0.37, driven mostly by a... More
Exelixis (EXEL) PT Lowered to $31 at Oppenheimer
February 13, 2019 7:58 AM ESTOppenheimer analyst Silvan Tuerkcan lowered the price target on Exelixis (NASDAQ: EXEL) to $31.00 (from $40.00) while maintaining a Outperform rating.
The analyst commented, "EXEL reported 4Q $176.2M revenue beating $170.0M consensus driven by Cabometyx sales of $171.6M vs $166M consensus. Cabometyx sales grew... More
Exelixis (EXEL) Tops Q4 EPS by 13c
February 12, 2019 4:07 PM ESTExelixis (NASDAQ: EXEL) reported Q4 EPS of $0.37, $0.13 better than the analyst estimate of $0.24. Revenue for the quarter came in at $228.6 million versus the consensus estimate of $188.76 million.
2019 Financial Guidance
The company is providing the following financial guidance for 2019. Cost of goods... More
